EBMT 2023 | Weighing up the pros and cons of CAR-T therapy and bispecific antibodies in R/R DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, compares benefits and drawbacks of CAR-T therapy and bispecific antibodies (BsAbs) in the context of relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL). Dr Sureda highlights the greater amount of follow-up data on CAR-T therapy, as well as the convenience of a ‘one-shot treatment’ while also acknowledging the more optimal toxicity profile, and enhanced accessibility of BsAbs. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
